Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.52 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486845 | 0.92 | GPR119 (0.69) | GPR119SMN1; SMN2KMT2AMEN1CYP2C19 | |
| SCHEMBL13757746 | 0.88 | SMN1; SMN2 (0.55) | GPR119SMN1; SMN2KMT2AMEN1CYP2C19 | |
| SCHEMBL3487767 | 0.85 | GPR119 (0.76) | GPR119SMN1; SMN2KMT2AMEN1CYP2C19 | |
| SCHEMBL3486537 | 0.83 | GPR119 (0.76) | GPR119SMN1; SMN2KMT2AMEN1CYP2C19 | |
| SCHEMBL8509255 | 0.83 | GPR119 (0.62) | GPR119SMN1; SMN2KMT2AMEN1CYP2C19 | |
| SCHEMBL3485718 | 0.82 | GPR119 (0.78) | GPR119SMN1; SMN2KMT2AMEN1CYP2C19 | |
| SCHEMBL3486856 | 0.82 | GPR119 (1.00) | GPR119KMT2AMEN1LMNAMAPT | |
| SCHEMBL2945397 | 0.82 | GPR119 (0.81) | GPR119KMT2ALMNAMAPT | |
| SCHEMBL10316012 | 0.81 | GPR119 (0.72) | GPR119SMN1; SMN2KMT2AMEN1CYP2C19 | |
| SCHEMBL10316006 | 0.81 | GPR119 (0.75) | GPR119SMN1; SMN2KMT2AMEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445499-B2 | Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8399485-B2 | Acyl bipiperidinyl compounds useful as GPR 119 agonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120178681-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100075987-A1 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075987-A1 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR27, FFAR2 | GPR119 1/4885SMN1; SMN2 3131/4885KMT2A 4306/4885 |
| US-20120178681-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR139, GPR27 | GPR119 1/4885SMN1; SMN2 3170/4885KMT2A 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.